Cover Image
Market Research Report

Lasmiditan (Migraine) - Forecast and Market Analysis to 2023

Published by GlobalData Product code 301158
Published Content info 55 Pages
Immediate Delivery Available
Price
Back to Top
Lasmiditan (Migraine) - Forecast and Market Analysis to 2023
Published: March 31, 2014 Content info: 55 Pages
Description

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

CoLucid Pharmaceuticals is developing Lasmiditan under a licensing agreement with Eli Lilly for the treatment of acute migraine. Lasmiditan is being developed to address the needs of two groups of patients, those with risk or diagnosis of cardiovascular disease, and those who have not had adequate efficacy from triptans. The drug is a neurally acting anti-migraine agent (NAAMA) that does not cause vasoconstriction, unlike other acute therapies such as the triptans, which also interact with 5-HT receptors located in the central and peripheral nervous systems.

Scope

  • Overview of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Lasmiditan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Lasmiditan for the top seven countries from 2012 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Migraine
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Lasmiditan performance
  • Obtain sales forecast for Lasmiditan from 2012-2023 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).
Table of Contents
Product Code: GDHC383DFR

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
  • 3.2. Symptoms
    • 3.2.1. Premonitory Phase
    • 3.2.2. Aura Phase
    • 3.2.3. Headache Phase
    • 3.2.4. Postdrome Phase

4. Disease Management

  • 4.1. Treatment Overview
    • 4.1.1. Acute Migraine Treatment
    • 4.1.2. Preventive Migraine Treatment

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Opportunity and Unmet Need

  • 6.1. Overview
    • 6.1.1. A Lack of Acute Therapies for Patients with or at Risk of Cardiovascular Disorders
    • 6.1.2. Lack of Acute Therapies for Patients Unresponsive to Triptan Medication
    • 6.1.3. Lack of Diagnostic Tools Causes Misdiagnosis
    • 6.1.4. Physician Education
    • 6.1.5. Effective and Well-Tolerated Prophylactic Therapies
  • 6.2. Unmet Needs Gap Analysis
    • 6.2.1. Acute Therapies for Patients with or at Risk of Cardiovascular Disorders and for Patients Unresponsive to Triptan Medication
    • 6.2.2. Effective and Well-Tolerated (Migraine-Specific) Preventive Therapies
    • 6.2.3. Physician Education
    • 6.2.4. Diagnostic Tools

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising drugs in clinical development

8. Lasmiditan

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement
  • 8.8. SWOT Analysis
  • 8.9. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Migraine Patients
    • 9.4.2. Percent Drug-treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic Erosion
    • 9.4.5. Pricing of Pipeline agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. Survey of Prescribing Physicians
  • 9.7. About the Authors
    • 9.7.1. Author
    • 9.7.2. Reviewer
    • 9.7.3. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Classification of Migraine Subtypes
  • Table 2: Diagnostic Criteria for Migraine with Aura
  • Table 3: Diagnostic Criteria for Migraine without Aura
  • Table 4: Treatment Guidelines for Migraine
  • Table 5: Most Prescribed Drugs for Migraine by Class in the Major Markets, 2013
  • Table 6: Overall Unmet Needs - Current Level of Attainment
  • Table 7: Clinical Unmet Needs - Gap Analysis, 2013
  • Table 8: Migraine - Promising Late-Stage Pipeline, 2013
  • Table 9: Comparison of Therapeutic Classes in Development for Migraine, 2013
  • Table 10: Product Profile - Lasmiditan
  • Table 11: Lasmiditan SWOT Analysis, 2013
  • Table 12: Global Sales Forecasts ($m) for lasmiditan, 2012-2023
  • Table 13: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Migraine Treatment Algorithm in the 7MM
  • Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Migraine, 2012-2023
Back to Top